Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-28T20:19:33.829Z Has data issue: false hasContentIssue false

Neuroleptic Malignant Syndrome: A case report and a literature review

Published online by Cambridge University Press:  01 September 2022

O. De Juan Viladegut*
Affiliation:
Hospital Clínic de Barcelona, Psychiatry And Psychology, Barcelona, Spain
M. Bioque
Affiliation:
Hospital Clínic de Barcelona, Psychiatry And Psychology, Barcelona, Spain
L. Ilzarbe
Affiliation:
Hospital Clínic de Barcelona, Psychiatry And Psychology, Barcelona, Spain
H. Andreu Gracia
Affiliation:
Hospital Clínic de Barcelona, Psychiatry And Psychology, Barcelona, Spain
L. Bueno Sanya
Affiliation:
Hospital Clínic de Barcelona, Psychiatry And Psychology, Barcelona, Spain
L. Olivier Mayorga
Affiliation:
Hospital Clínic de Barcelona, Psychiatry And Psychology, Barcelona, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Neuroleptic malignant syndrome (NMS) may be a life-threatening neurologic crisis primarily emerging as an idiosyncratic reaction to antipsychotic agent use, and characterized by a particular clinical syndrome of mental status alter, rigidity, fever and dysautonomia. Mortality results straightforwardly from the dysautonomic manifestations of the disease and from systemic complications.

Objectives

To describe an unusual clinical case in order to determine the management regarding medication and electroconvulsive therapy (ECT), and provide an overview of NMS for the general practitioner with the most up-to-date information on etiology, workup, and management.

Methods

We report a case involving a 55-year-old man with paranoid schizophrenia disorder who presented with hyperthermia, hemodynamic instability, miosis, muscular rigidity, urinary incontinence, catatonic signs and mutism after combining several antipsychotics at the same time: long-acting injectable form of paliperidone, aripiprazol and haloperidol.

Results

Guidelines for specific medical treatments in NMS are based upon case reports and clinical experience. Generally used agents are dantrolene, bromocriptine, and amantadine. A conceivable approach is to start with benzodiazepines along with dantrolene in moderate or severe cases, followed by the addition of bromocriptine or amantadine. ECT is generally reserved for patients not responding to other treatments.

Conclusions

NMS is an uncommon adverse drug reaction, with a multifactor pathophysiology and manifestation. Early diagnosis and interruption of antipsychotic therapy is the first-line treatment, followed by supportive care and pharmacotherapy. ECT is an effective treatment when supportive treatment together with pharmacotherapy fails. It could be considered first line in severe life-threatening situations. It is advisable to consider maintenance ECT due to the high risk of relapse.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.